MIAMI, Jan. 28, 2015 — Sailormen Inc., the largest domestic franchisee of Popeyes Louisiana Kitchen restaurants, and the Muscular Dystrophy Association today announced the kickoff of the 13th annual “Appetite for a Cure” campaign that will raise critical funds and awareness to help MDA save and improve the lives of children and adults fighting muscle disease.
Major League Baseball’s Commitment to Fighting ALS and
The ALS Ice Bucket Challenge Spurs Funding
WASHINGTON/CHICAGO, December 3, 2014 — The ALS Association and Muscular Dystrophy Association (MDA) have joined forces to fund a research project aimed at finding a potential therapy for amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig’s Disease. Both nonprofits are focused on finding treatments and cures for ALS and providing services for those affected with the debilitating, fatal disease.
CHICAGO, Aug. 4, 2014 — A drug called ataluren (brand name Translarna), in development to treat a subset of patients with Duchenne muscular dystrophy (DMD) has received "conditional approval" in the European Union.
This is the first drug specifically developed for and tested in Duchenne muscular dystrophy to receive approval in any country. PTC Therapeutics, the drug’s developer, announced the approval in an Aug. 4, 2014, press release.
SOUTH PLAINFIELD, N.J., Aug. 4, 2014 — PTC Therapeutics, Inc. today announced that the European Commission has granted conditional marketing authorization for Translarna™ (ataluren), in the European Union (EU) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients aged five years and older.